Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

Impact · against what's priced in

The five-year data for AMVUTTRA is fundamentally a confirmation of the drug's existing profile and does not shift the valuation thesis. Because the market already assumes a near-term commercial monopoly for the drug in TTR silencing, sustained benefit data is a predicted outcome rather than a new catalyst.

ALNY+0.05

Already priced in

The price assumes

The near-term commercial monopoly for AMVUTTRA in TTR silencing